ORIGINAL_ARTICLE
Arsenic Trioxide; a Novel Therapeutic Agent for Prostate and Bladder Cancers
The effectiveness of arsenic trioxide (ATO) in treating blood diseases is one of the most striking developments in modern medicine. One of the most essential benefits of ATO is the failure of bone marrow suppression. ATO has been proposed as a novel and effective medicine for cancer prevention and treatment with various functions, including induction of apoptosis through re-activating the Wnt inhibitor, growth inhibition via activation of phosphatidylinositol 3-kinase (PI3K)/AKT pathway, autophagy stimulation, induction of cell differentiation and angiogenesis via vascular endothelial growth factor A (VEGFA)-VEGFR2-PI3K/ extracellular signal‐regulated kinase (ERK) signaling path in cancer cells and ATO may be involved in the acetylation of histones and interfering with gene transcription. ATO can increase the synergistic effect in treatment and increase antitumor effects on prostate cancer cells via inhibiting Akt/mTOR signaling pathways. So, ATO, combined with inhibiting glutathione synthesis, can effectively treat bladder cancer epithelial cells.
http://www.transresurology.com/article_105001_797d08ec0622a6bd5718a3818bd807f0.pdf
2019-08-10
1
7
10.22034/au.2020.223726.1011
Arsenic trioxide
cancer cells
Angiogenesis
Apoptosis
Akram
Mirzaei
mirzaee.scholar@gmail.com
1
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Leila
Zareian Baghdadabad
zareian@farabi.tums.ac.ir
2
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad Hatef
Khorrami
khorami@med.mui.ac.ir
3
Department of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
AUTHOR
Seyed Mohammad Kazem
Aghamir
mkaghamir@tums.ac.ir
4
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Amadori S, Fenaux P, Ludwig H, O’dwyer M, Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Current medical research and opinion. 2005;21(3):403-11.
1
2. Bae-Jump VL, Zhou C, Boggess JF, Gehrig PA. Arsenic trioxide (As2O3) inhibits expression of estrogen receptor—alpha through regulation of the mitogen-activated protein kinase (MAPK) pathway in endometrial cancer cells. Reproductive Sciences. 2008;15(10):1011-7.
2
3. Graeme KA, Pollack Jr CV. Heavy metal toxicity, part I: arsenic and mercury. The Journal of emergency medicine. 1998;16(1):45-56.
3
4. Genç M, Ledger WJ. Syphilis in pregnancy. Sexually transmitted infections. 2000;76(2):73-9.
4
5. Yedjou C, Tchounwou P, Jenkins J, McMurray R. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. Journal of hematology & oncology. 2010;3(1):28.
5
6. Wang Z-Y. Arsenic compounds as anticancer agents. Cancer chemotherapy and pharmacology. 2001;48(1):S72-S6.
6
7. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology. 2001;19(18):3852-60.
7
8. Kroemer G, de Thé H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? Journal of the National Cancer Institute. 1999;91(9):743-5.
8
9. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. Journal of Clinical Oncology. 2010;28(24):3866-71.
9
10. Mao M-H, Huang H-B, Zhang X-L, Li K, Liu Y-L, Wang P. Additive antitumor effect of arsenic trioxide combined with intravesical bacillus Calmette–Guerin immunotherapy against bladder cancer through blockade of the IER3/Nrf2 pathway. Biomedicine & Pharmacotherapy. 2018;107:1093-103.
10
11. Luo D, Zhang X, Du R, Gao W, Luo N, Zhao S, et al. Low dosage of arsenic trioxide (As 2 O 3) inhibits angiogenesis in epithelial ovarian cancer without cell apoptosis. JBIC Journal of Biological Inorganic Chemistry. 2018;23(6):939-47.
11
12. Zhong L, Xu F, Chen F. Arsenic trioxide induces the apoptosis and decreases NF‑κB expression in lymphoma cell lines. Oncology letters. 2018;16(5):6267-74.
12
13. Du S, Liu K, Gao P, Li Z, Zheng J. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status. Life sciences. 2018;212:182-93.
13
14. Zhang L, Liu L, Zhan S, Chen L, Wang Y, Zhang Y, et al. Arsenic trioxide suppressed migration and angiogenesis by targeting FOXO3a in gastric cancer cells. International journal of molecular sciences. 2018;19(12):3739.
14
15. Zheng L, Jiang H, Zhang Z-W, Wang K-N, Wang Q-F, Li Q-L, et al. Arsenic trioxide inhibits viability and induces apoptosis through reactivating the Wnt inhibitor secreted frizzled related protein-1 in prostate cancer cells. OncoTargets and therapy. 2016;9:885.
15
16. Yuan Z, Wang F, Zhao Z, Zhao X, Qiu J, Nie C, et al. BIM-mediated AKT phosphorylation is a key modulator of arsenic trioxide-induced apoptosis in cisplatin-sensitive and-resistant ovarian cancer cells. PLoS One. 2011;6(5).
16
17. Han YH, Kim SZ, Kim SH, Park WH. Arsenic trioxide inhibits growth of As4. 1 juxtaglomerular cells via cell cycle arrest and caspase-independent apoptosis. American journal of physiology-renal physiology. 2007;293(2):F511-F20.
17
18. Huang Y, Du K, Xue Z, Yan H, Li D, Liu W, et al. Cobalt chloride and low oxygen tension trigger differentiation of acute myeloid leukemic cells: possible mediation of hypoxia-inducible factor-1 α. Nature Publishing Group; 2003.
18
19. Armitage JO, Carbone PP, Connors JM, Levine A, Bennett JM, Kroll S. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin’s lymphoma patients. Journal of Clinical Oncology. 2003;21(5):897-906.
19
20. Kodigepalli KM, Dutta PS, Bauckman KA, Nanjundan M. SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS letters. 2013;587(1):5-16.
20
21. Park WH, Cho YH, Jung CW, Park JO, Kim K, Im YH, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochemical and biophysical research communications. 2003;300(1):230-5.
21
22. La Rosée P, Johnson K, O'Dwyer ME, Druker BJ. In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia. Experimental hematology. 2002;30(7):729-37.
22
23. Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. The oncologist. 2001;6(90002):22-8.
23
24. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide–induced cytotoxicity in multiple myeloma cells. Blood, The Journal of the American Society of Hematology. 2001;98(3):805-13.
24
25. Lengfelder E, Hofmann W, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia. 2012;26(3):433-42.
25
26. Chiu H-W, Chen Y-A, Ho S-Y, Wang Y-J. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and-independent human prostate cancer cells. PloS one. 2012;7(2).
26
27. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, Kakehi Y, et al. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer research. 2001;61(14):5432-40.
27
28. Yu J, Qian H, Li Y, Wang Y, Zhang X, Liang X, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecologic oncology. 2007;106(2):400-6.
28
29. Jutooru I, Chadalapaka G, Sreevalsan S, Lei P, Barhoumi R, Burghardt R, et al. Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth. Experimental cell research. 2010;316(13):2174-88.
29
30. Balakumar P, Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovascular toxicology. 2009;9(4):169-76.
30
31. Reichl F, Szinicz L, Kreppel H, Fichtl B, Forth W. Effect of glucose in mice after acute experimental poisoning with arsenic trioxide (As 2 O 3). Archives of toxicology. 1990;64(4):336-8.
31
32. Liu S, Guo X, Wu B, Yu H, Zhang X, Li M. Arsenic induces diabetic effects through beta-cell dysfunction and increased gluconeogenesis in mice. Scientific reports. 2014;4:6894.
32
33. Zheng L, Kuo C-C, Fadrowski J, Agnew J, Weaver VM, Navas-Acien A. Arsenic and chronic kidney disease: a systematic review. Current environmental health reports. 2014;1(3):192-207.
33
34. Sińczuk-Walczak H, Szymczak M, Hałatek T. Effects of occupational exposure to arsenic on the nervous system: clinical and neurophysiological studies. International journal of occupational medicine and environmental health. 2010;23(4):347-55.
34
35. Kannan GM, Tripathi N, Dube SN, Gupta M, Flora S, Flora SJ. Toxic effects of arsenic (III) on some hematopoietic and central nervous system variables in rats and guinea pigs. Journal of Toxicology: Clinical Toxicology. 2001;39(7):675-82.
35
36. Song C, Zhao J, Fu B, Li D, Mao T, Peng W, et al. Melatonin-mediated upregulation of Sirt3 attenuates sodium fluoride-induced hepatotoxicity by activating the MT1-PI3K/AKT-PGC-1α signaling pathway. Free Radical Biology and Medicine. 2017;112:616-30.
36
37. Rossman TG, Uddin AN, Burns FJ. Evidence that arsenite acts as a cocarcinogen in skin cancer. Toxicology and applied pharmacology. 2004;198(3):394-404.
37
38. Jahovic N, Çevik H, Şehirli AÖ, Yeğen BÇ, Şener G. Melatonin prevents methotrexate‐induced hepatorenal oxidative injury in rats. Journal of pineal research. 2003;34(4):282-7.
38
39. Kumar S, Yedjou CG, Tchounwou PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. Journal of experimental & clinical cancer research. 2014;33(1):42.
39
40. Kozono S, Lin Y-M, Seo H-S, Pinch B, Lian X, Qiu C, et al. Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells. Nature communications. 2018;9(1):1-17.
40
41. Feng-lian Q, Yan-fen L, Yun-xia W, Jian-hui M, Wei S, Da-tong C, et al. Effects of arsenic trioxide on human renal cell carcinoma lines in vitro. Chinese Journal of Integrative Medicine. 2004;10(1):48-51.
41
42. Tai S, Xu L, Xu M, Zhang L, Zhang Y, Zhang K, et al. Combination of Arsenic trioxide and Everolimus (Rad001) synergistically induces both autophagy and apoptosis in prostate cancer cells. Oncotarget. 2017;8(7):11206.
42
43. Pu Y-S, Hour T-C, Chen J, Huang C-Y, Guan J-Y, Lu S-H. Cytotoxicity of arsenic trioxide to transitional carcinoma cells. Urology. 2002;60(2):346-50.
43
44. Bornstein J, Sagi S, Haj A, Harroch J, Fares F. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. Gynecologic oncology. 2005;99(3):726-9.
44
45. Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner‐Hofmann T. Enhancement of arsenic trioxide‐mediated apoptosis using docosahexaenoic acid in arsenic trioxide‐resistant solid tumor cells. International Journal of Cancer. 2004;112(4):707-12.
45
46. Chiu H-W, Chen Y-A, Ho S-Y, Wang Y-J. Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and-independent human prostate cancer cells. PloS one. 2012;7(2):e31579.
46
47. Isakson P, Bjørås M, Bøe SO, Simonsen A. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood, The Journal of the American Society of Hematology. 2010;116(13):2324-31.
47
48. Kwong RC, Karagas MR, Kelsey KT, Mason RA, Tanyos SA, Schned AR, et al. Arsenic exposure predicts bladder cancer survival in a US population. World journal of urology. 2010;28(4):487-92.
48
49. Patlolla AK, Tchounwou PB. Cytogenetic evaluation of arsenic trioxide toxicity in Sprague–Dawley rats. Mutation Research/Genetic Toxicology and Environmental Mutagenesis. 2005;587(1-2):126-33.
49
50. Li Y, Yu G, Li Q, Wang W, Shen X, Liu H, et al. Construction of a BALB/c-Nu mouse model of invasive bladder carcinoma and preliminary studies on the treatment of bladder tumors through internal iliac arterial infusion of albumin-bound arsenic trioxide (As2O3). PloS one. 2015;10(4).
50
ORIGINAL_ARTICLE
Laparoscopic Injection of Methylene Blue to Discriminate Cyst from Calyceal Diverticulum
Introduction Renal cysts are sacs of fluid with a thin wall, usually with no symptoms, and have no connection to the renal calyx. Another renal lesion that can be misdiagnosed with cysts is the calyceal diverticulum linked to the renal calyx. The new approach of laparoscopic injection of methylene blue can help the surgeon distinguish renal cysts from a calyceal diverticulum in a patient with no double J (Dj/JJ).Case presentationA 52-years patient with a 15 cm lesion underwent laparoscopic surgery of a renal cyst. Surgery was done in the flank position, and the peritoneoscopy was performed after the cyst reveal. Several small cysts were observed at the bottoms of the cyst, so we injected methylene blue to make it clear this lesion was exactly cysts, not calyceal diverticulum. It was proven that there is no leaking of blue color to the renal calyx through the catheter. The cyst was revealed and was removed and sent for pathology.ConclusionsIn our study, the laparoscopic injection of methylene blue indicated no connection with the renal calyx, so the lesion is a renal cyst. So it can be a new approach for distinguishing cysts from a calyceal diverticulum.
http://www.transresurology.com/article_106221_75e982be8f4ee8258abaa9c8edfa33e1.pdf
2019-08-12
8
11
10.22034/au.2020.221836.1008
renal cyst
calyceal diverticulum
Laparoscopy
Seyed Mohammad Kazem
Aghamir
mkaghamir@tums.ac.ir
1
Urology research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Fatemeh
Khatami
fatemehkhatami1978@gmail.com
2
Urology research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Hamidreza
Zia
ziahamidreza@gmail.com
3
Urology research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Terada N, Ichioka K, Matsuta Y, Okubo K, Yoshimura K, Arai Y. The natural history of simple renal cysts. The Journal of urology. 2002;167(1):21-3.
1
2. Caglioti A, Esposito C, Fuiano G, Buzio C, Postorino M, Rampino T, et al. Prevalence of symptoms in patients with simple renal cysts. BMJ: British Medical Journal. 1993;306(6875):430.
2
3. Bisceglia M, Galliani CA, Senger C, Stallone C, Sessa A. Renal cystic diseases: a review. Advances in anatomic pathology. 2006;13(1):26-56.
3
4. Mensel B, Kühn J-P, Kracht F, Völzke H, Lieb W, Dabers T, et al. Prevalence of renal cysts and association with risk factors in a general population: an MRI-based study. Abdominal Radiology. 2018;43(11):3068-74.
4
5. Bonsib SM. Renal cystic diseases and renal neoplasms: a mini-review. Clinical Journal of the American Society of Nephrology. 2009;4(12):1998-2007.
5
6. Middleton AW, Pfister RC. Stone-containing pyelocaliceal diverticulum: embryogenic, anatomic, radiologic and clinical characteristics. The Journal of urology. 1974;111(1):2-6.
6
7. Kilinc M, Tufan O, Guven S, Odev K, Gurbuz R. Percutaneous injection sclerotherapy with tetracycline hydrochloride in simple renal cysts. International urology and nephrology. 2008;40(3):609-13.
7
8. Hanna R, Dahniya M. Aspiration and sclerotherapy of symptomatic simple renal cysts: value of two injections of a sclerosing agent. AJR American journal of roentgenology. 1996;167(3):781-3.
8
9. Karmazyn B, Kaefer M, Jennings SG, Nirmala R, Raske ME. Caliceal diverticulum in pediatric patients: the spectrum of imaging findings. Pediatric radiology. 2011;41(11):1369-73.
9
10. Estrada CR, Datta S, Schneck FX, Bauer SB, Peters CA, Retik AB. Caliceal diverticula in children: natural history and management. The Journal of urology. 2009;181(3):1306-11.
10
11. Canales B, Monga M. Surgical management of the calyceal diverticulum. Current opinion in urology. 2003;13(3):255-60.
11
12. Hemal AK. Laparoscopic management of renal cystic disease. Urologic Clinics of North America. 2001;28(1):115-26.
12
13. Polom W, Markuszewski M, Rho YS, Matuszewski M. Usage of invisible near infrared light (NIR) fluorescence with indocyanine green (ICG) and methylene blue (MB) in urological oncology. Part 1. Central European journal of urology. 2014;67(2):142.
13
14. Roberts WW, Bluebond-Langner R, Boyle KE, Jarrett TW, Kavoussi LR. Laparoscopic ablation of symptomatic parenchymal and peripelvic renal cysts. Urology. 2001;58(2):165-9.
14
15. Wang Z, Zeng X, Chen C, Wang T, Chen R, Liu J. Methylene Blue Injection via Percutaneous Renal Cyst Puncture Used in Flexible Ureteroscope for Treatment of Parapelvic Cysts: A Modified Method for Easily Locating Cystic Wall. Urology. 2019;125:243-7.
15
ORIGINAL_ARTICLE
Impact of Bone Mineral Density on the Recurrent Urolithiasis
IntroductionPatients with urinary stones have calcium metabolism deficiencies, leading to excessive calcium absorption from their bones. This phenomenon may expose these individuals to osteoporosis. This study evaluated bone mineral density (BMD) in patients with urinary stones in Iran.MethodsThis is an analytical case-control study performed in Sina hospital from March 2016 to January 2018. Twenty-four male patients between 30 and 50 with recurrent urinary tract stones were enrolled in the study. The control group was selected from the same period and sex group with no history of urinary stone formation. The diet was similar in the two groups. The sampling method was non-random. Age and BMI were considered confounding variables. After completing, the questionnaire measured the BMD of the lumbar spine (L4 L2) and the femoral neck. The data were analyzed using linear regression and t-test.ResultsIn both regions, BMD was significantly lower in patients compared to the control group (p-value<0.01). Besides, there was a significant correlation between the duration of urinary stones and BMD in each of the mentioned areas (p-value<0.001, r=-0.73 in the lumbar spine, p-valueConclusionsReduction of bone density in patients with recurrent urinary stones may indicate a primary impairment in the bone metabolism of these individuals. Considering that 30% of patients have osteopenia and, generally, patients with urinary stones are not allowed to use calcium, it is necessary to eliminate calcium from their diets only after complete analysis.
http://www.transresurology.com/article_106324_2a4056c94112c2c774b63a865cd785f5.pdf
2019-08-15
12
16
10.22034/au.2020.227228.1014
Osteoporosis
Urine
Stone
Bone mineral density
Abdolrasoul
Mehrsai
mehrsai@yahoo.com
1
Urology Research Center,Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Elham
Hashemian Naeini
ehashemiannaeini@gmail.com
2
Department of Gynecological Oncology, Mirza Koochak Khan Hospital, Tehran, Iran
AUTHOR
Fatemeh
Dadkhah Tehrani
mahsal374@aut.ac.ir
3
Department of Biomadical Engineering, Amirkabir University of Technology, Tehran, Iran
AUTHOR
Keramatollah
Noori Jalayani
k.njalayani@gmail.com
4
Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
1. Robertson W, Peacock M, Baker M, Marshall D, Pearlman B, Speed R, et al. Studies on the prevalence and epidemiology of urinary stone disease in men in Leeds. British journal of urology. 1983;55(6):595-8.
1
2. Park S, Pearle MS. Pathophysiology and management of calcium stones. Urologic Clinics of North America. 2007;34(3):323-34.
2
3. Beara-Lasic L, Goldfarb DS. Recurrent Calcium Kidney Stones. Clinical Journal of the American Society of Nephrology. 2019:CJN. 02550319.
3
4. Fuss M, Gillet C, Simon J, Vandewalle J-C, Schoutens A, Bergmann PJEu. Bone mineral content in idiopathic renal stone disease and in primary hyperparathyroidism. 1983;9:32-4.
4
5. Alhava E, Juuti M, Karjalainen PJSjou, nephrology. Bone mineral density in patients with urolithiasis: A preliminary report. 1976;10(2):154-6.
5
6. Kinai E, Gatanaga H, Mizushima D, Nishijima T, Aoki T, Genka I, et al. Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration. Journal of Infection and Chemotherapy. 2017;23(5):259-64.
6
7. Pietschmann F, Breslau NA, Pak CYJJoB, Research M. Reduced vertebral bone density in hypercalciuric nephrolithiasis. 1992;7(12):1383-8.
7
8. Schwaderer AL, Oduguwa A, Kusumi K. Urinary stone disease in pediatric and adult metabolic bone clinic patients. Urolithiasis. 2018;46(2):173-8.
8
9. Bartges JW. Feline calcium oxalate urolithiasis: risk factors and rational treatment approaches. Journal of Feline medicine and Surgery. 2016;18(9):712-22.
9
10. Westropp JL, Lulich J. Medical management of urolithiasis. BSAVA Manual of Canine and Feline Nephrology and Urology: BSAVA Library; 2017. p. 304-10.
10
11. D’Alessandro C, Ferraro PM, Cianchi C, Barsotti M, Gambaro G, Cupisti A. Which diet for calcium stone patients: A real-world approach to preventive care. Nutrients. 2019;11(5):1182.
11
12. Chapurlat R, Pialat J-B, Merle B, Confavreux E, Duvert F, Fontanges E, et al. The QUALYOR (QUalite Osseuse LYon Orleans) study: a new cohort for non invasive evaluation of bone quality in postmenopausal osteoporosis. Rationale and study design. Archives of osteoporosis. 2018;13(1):2.
12
13. Emer MÖ, İnce S, Arslan N. Bone Mineral Densitometry: Measurement and Evaluation Methods. Musculoskeletal Research and Basic Science: Springer; 2016. p. 197-212.
13
14. Wolman DN, Patel BP, Wintermark M, Heit JJ. Dual-Energy Computed Tomography Applications in Neurointervention. Journal of computer assisted tomography. 2018;42(6):831-9.
14
15. Mei K, Schwaiger BJ, Kopp FK, Ehn S, Gersing AS, Kirschke JS, et al. Bone mineral density measurements in vertebral specimens and phantoms using dual-layer spectral computed tomography. Scientific reports. 2017;7(1):17519.
15
16. Cherif R, Vico L, Laroche N, Sakly M, Attia N, Lavet C. Dual-energy X-ray absorptiometry underestimates in vivo lumbar spine bone mineral density in overweight rats. Journal of bone and mineral metabolism. 2018;36(1):31-9.
16
17. Fredenberg E. Spectral and dual-energy X-ray imaging for medical applications. Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2018;878:74-87.
17
18. Buckinx F, Landi F, Cesari M, Fieding RA, Visser M, Engelke K, et al. The Authors reply:“Dual energy X‐ray absorptiometry: gold standard for muscle mass?” by Scafoglieri et al. Journal of cachexia, sarcopenia and muscle. 2018;9(4):788.
18
19. Lowitz T, Museyko O, Bousson V, Chappard C, Laouisset L, Laredo J-D, et al. Advanced Knee Structure Analysis (AKSA): a comparison of bone mineral density and trabecular texture measurements using computed tomography and high-resolution peripheral quantitative computed tomography of human knee cadavers. Arthritis research & therapy. 2017;19(1):1.
19
20. Sakhaee K, Maalouf NM, Poindexter J, Adams-Huet B, Moe OW. Relationship between urinary calcium and bone mineral density in patients with calcium nephrolithiasis. The Journal of urology. 2017;197(6):1472-7.
20
21. TRINCHIERI A, NESPOLI R, OSTINI F, ROVERA F, ZANETTI G, PISANI EJTJou. A study of dietary calcium and other nutrients in idiopathic renal calcium stone formers with low bone mineral content. 1998;159(3):654-7.
21
22. Shavit L, Girfoglio D, Vijay V, Goldsmith D, Ferraro PM, Moochhala SH, et al. Vascular calcification and bone mineral density in recurrent kidney stone formers. Clinical Journal of the American Society of Nephrology. 2015;10(2):278-85.
22
23. Wardle E, Kurihara I, Saito T, Obara K, Shoji Y, Hirai M, et al. Bone mineral density in patients with hypercalciuric nephrolithiasis. Nephron. 1996;73(4):557-60.
23
24. Bijelic R, Milicevic S, Balaban J. Correlation of osteoporosis and calcium urolithiasis in adult population. medical archives. 2016;70(1):66.
24
ORIGINAL_ARTICLE
Equivalency of First-Void Urine Culture with Prostatic Secretion Fluids
IntroductionThe purpose of the current study was to investigate the separation of the bacterial factors of men’s urinary tract infections using the prostate massage technique and compare them with the initial-stream, midstream, and end-stream urine in Tehran’s Health Centers. MethodsThis study collected samples from 50 men with genital-urinary tract defects who were referred to medical centers. Patients were asked for demographic information, medical history, and drugs taken during sampling. Prostate secretions and first-void urine (VB1) were collected from the first 25 patients; prostate secretions and VB1, midstream urine (VB2), and end-stream urine (VB3) were collected from the second 25 patients.ResultsUsing prostate secretions culture, out of the first 25 samples, 7 samples (28%) were infected by Mycoplasma hominis and 9 samples (36%) were infected by Ureaplasma urealyticum. using VB1 culture, it was analyzed that 6 samples (24%) were infected by Mycoplasma hominis and 8 samples (32%) were infected by Ureaplasma urealyticum. In the second 25 samples, Bacterial contamination was seen in 23 samples (92%) by prostate secretions culture. VB1 culture showed bacterial contamination in 14 samples (56%). VB2 and VB3 cultures showed bacterial contamination in 3 (12%) and only 2 samples (8%).ConclusionsIn conclusion, the results obtained from the prostate secretions culture were more accurate and precise than the VB1 culture, but they were close to each other. Therefore, instead of using prostate massage, which can be irritating for the patients or if the patient does not have prostate secretions, VB1 culture can be used.
http://www.transresurology.com/article_106610_c1d17671ff9d1ab84fcc232cb6c61c6c.pdf
2019-08-17
17
22
10.22034/au.2020.221850.1010
prostate massage
Urinary tract infection
Bacterial factors
bacterial prostatitis
Kiumars
Ghazisaidi
kiumarsghazisaidi@yahoo.com
1
Infectious Disease Research Center, Golestan University of Medical Sciences, Gorgan, Iran
AUTHOR
Yasaman
Azimi
azimiyasaman4@gmail.com
2
Department of Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Ali
Samadi
a.samadi99@yahoo.com
3
Department of Genetics and Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
AUTHOR
Seyed Mohammad Kazem
Aghamir
mkaghamir@tums.ac.ir
4
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Maryam
Aghaii
ma.aghaii@yahoo.com
5
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Gholamreza
Pourmand
gh_pourmand@yahoo.com
6
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Wagenlehner F, Tandogdu Z, Bartoletti R, Cai T, Cek M, Kulchavenya E, et al. The global prevalence of infections in urology study: a long-term, worldwide surveillance study on urological infections. Pathogens. 2016;5(1):10.
1
2. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews microbiology. 2015;13(5):269-84.
2
3. Busolo F, Zanchetta R, Lanzone E, Cusinato R. Microbial flora in semen of asymptomatic infertile men. Andrologia. 1984;16(3):269-75.
3
4. Witkin SS, Toth A. Relationship between genital tract infections, sperm antibodies in seminal fluid, and infertility. Fertility and sterility. 1983;40(6):805-8.
4
5. Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, et al. Risk factors for recurrent urinary tract infection and renal scarring. Pediatrics. 2015;136(1):e13-e21.
5
6. Klein EA, Silverman R. Inflammation, infection, and prostate cancer. Current opinion in urology. 2008;18(3):315-9.
6
7. Khan FU, Ihsan AU, Khan HU, Jana R, Wazir J, Khongorzul P, et al. Comprehensive overview of prostatitis. Biomedicine & Pharmacotherapy. 2017;94:1064-76.
7
8. Meares EM. Prostatitis syndromes: new perspectives about old woes. The Journal of urology. 1980;123(2):141-7.
8
9. Alshahrani S, McGill J, Agarwal A. Prostatitis and male infertility. Journal of reproductive immunology. 2013;100(1):30-6.
9
10. Radonić A, Kovacević V, Markotić A, Skerk V, Turcić P. The clinical significance of Ureaplasma urealyticum in chronic prostatitis. Journal of chemotherapy (Florence, Italy). 2009;21(4):465-6.
10
11. Rees J, Abrahams M, Doble A, Cooper A, Group PER. Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline. BJU international. 2015;116(4):509-25.
11
12. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clinical Infectious Diseases. 2010;50(12):1641-52.
12
13. Weidner W, Brunner H, Krause W. Quantitative culture of Ureaplasma urealyticum in patients with chronic prostatitis or prostatosis. The Journal of urology. 1980;124(5):622-5.
13
14. Kim T-H, Kim HR, Myung S-C. Detection of nanobacteria in patients with chronic prostatitis and vaginitis by reverse transcriptase polymerase chain reaction. Korean journal of urology. 2011;52(3):194-9.
14
15. Cao B, Ren L-L, Zhao F, Gonzalez R, Song S-F, Bai L, et al. Viral and Mycoplasma pneumoniae community-acquired pneumonia and novel clinical outcome evaluation in ambulatory adult patients in China. European journal of clinical microbiology & infectious diseases. 2010;29(11):1443-8.
15
16. Jensen JS, Cusini M, Gomberg M, Moi H. 2016 European guideline on Mycoplasma genitalium infections. Journal of the European Academy of Dermatology and Venereology. 2016;30(10):1650-6.
16
17. Meyer KM, Leveau JH. Microbiology of the phyllosphere: a playground for testing ecological concepts. Oecologia. 2012;168(3):621-9.
17
18. Weinstein SA, Stiles BG. Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium. Expert review of anti-infective therapy. 2012;10(4):487-99.
18
19. MAEDA SI, Deguchi T, Ishiko H, Matsumoto T, Naito S, Kumon H, et al. Detection of Mycoplasma genitalium, Mycoplasma hominis, Ureaplasma parvum (biovar 1) and Ureaplasma urealyticum (biovar 2) in patients with non‐gonococcal urethritis using polymerase chain reaction‐microtiter plate hybridization. International journal of urology. 2004;11(9):750-4.
19
20. McGowan M, Burger H, Baker H, De Kretser D, Kovacs G. The incidence of non‐specific infection in the semen in fertile and sub‐fertile males. International journal of andrology. 1981;4(1‐6):657-62.
20
21. Clyde Jr WA. Mycoplasma pneumoniae infections of man. The mycoplasmas. 2012;2:275-306.
21
22. Waites KB, Duffy LB, Bébéar CM, Matlow A, Talkington DF, Kenny GE, et al. Standardized methods and quality control limits for agar and broth microdilution susceptibility testing of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. Journal of clinical microbiology. 2012;50(11):3542-7.
22
23. Cummins DR. An avidin-biotin enhanced dot-immunobinding assay for the detection of serum antibodies to avian mycoplasmas. 1989.
23
24. McCutchan JA. Epidemiology of venereal urethritis: comparison of gonorrhea and nongonococcal urethritis. Reviews of infectious diseases. 1984;6(5):669-88.
24
25. Al‐Sweih NA, Al‐Fadli AH, Omu AE, Rotimi VO. Prevalence of Chlamydia trachomatis, Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections and seminal quality in infertile and fertile men in Kuwait. Journal of andrology. 2012;33(6):1323-9.
25
26. Golden MR, Handsfield HH. Neisseria Gonorrhoeae Infections. Goldman's Cecil Medicine: Elsevier; 2012. p. e144-e9.
26
27. Nickel JC, Shoskes D, Wang Y, Alexander RB, Fowler JE, Zeitlin S, et al. How does the pre-massage and post-massage 2-glass test compare to the Meares-Stamey 4-glass test in men with chronic prostatitis/chronic pelvic pain syndrome? The Journal of urology. 2006;176(1):119-24.
27
ORIGINAL_ARTICLE
An Unusual Extrarenal Renal Cell Carcinoma: Case Report
IntroductionRenal cell carcinoma (RCC) is the most common type of kidney tumor. The extra-renal type has been previously reported only by a few studies. In this type of RCC, cancerous tissue is present in regions other than the kidney. Here we present an isolated renal mass (RM), primarily diagnosed as an adrenal mass.Case presentationA 52-year-old male presented with left flank pain without weight loss, visible hematuria, and hydronephrosis was the case of this study. Computed tomography (CT) scan revealed a mass that could be either an adrenal tumor, retroperitoneal diagnosis, or a renal upper bridge tumor. The kidney mass was seen above the junction of the middle and upper renal bridges. Its surrounding was liberated from the Gerota. The kidney mass was independent and encapsulated of the kidney but adhered to its surface. It was gradually released from the capsule and extracted. The capsule beneath the mass was intact, and the site had no bleeding. The mass was then placed in endobag and removed from port ten, and the entrance of port ten was sutured during a six-month follow-up there was no hydronephrosis and no evidence of urinoma around the kidney.ConclusionsRare cases of extrarenal RCC, which attach to the kidney, Can be removed without any damage to the kidney.
http://www.transresurology.com/article_106624_361d8ea5a30129def542d687c395cf7f.pdf
2019-08-23
23
26
10.22034/au.2020.227372.1015
Carcinoma
Renal Cell
kidney neoplasms
Malignancy
Fateme
Guitynavard
f_guitynavard@ymail.com
1
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Seyed Habibollah
Mousavibahar
shmousavibahar@gmail.com
2
Urology and Nephrology Research Center, Hamedan University of Medical Sciences, Hamedan, Iran
AUTHOR
Fatemeh
Dadkhah Tehrani
mahsal374@aut.ac.ir
3
Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran
AUTHOR
Arezoo
Eftekhar Javadi
afjavadi99@gmail.com
4
Department of Pathology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Hamidreza
zia
hamidreza.zia99@gmail.com
5
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. 2018;103:356-87.
1
2. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, et al. The changing pattern of kidney cancer incidence and mortality in Europe. 2008;101(8):949-58.
2
3. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. 2019;75(5):799-810.
3
4. Thorstenson A, Bergman M, Scherman-Plogell A-H, Hosseinnia S, Ljungberg B, Adolfsson J, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register. 2014;48(3):231-8.
4
5. Terada TJPi. Extra-renal clear cell renal cell carcinoma probably arising from mesodermal embryonic remnants. 2012;62(4):291-3.
5
6. Roumina Hasan SK, Monappa V, Ayachit AJUa. Primary extra-renal clear cell renal cell carcinoma masquerading as an adrenal mass: A diagnostic challenge. 2015;7(4):513.
6
7. Li Y, Qiu X, Li W, Yang Y, Yang R, Zhao X, et al. Primary Extrarenal Type 2 Papillary Renal Cell Carcinoma: A Case Report. 2019;123:e1-e3.
7
8. Nunes G, Pinto-Marques P, Sequeira P, Mendonça EJG-PJoG. Primary Extrarenal Renal Cell Carcinoma: A Unique Diagnosis Performed through Endoscopic Ultrasound. 2019;26(5):378-80.
8
9. Costantino C, Thomas GV, Ryan C, Coakley FV, Troxell MLJIu, nephrology. Metastatic renal cell carcinoma without evidence of a renal primary. 2016;48(1):73-7.
9
10. Terada T. Extra-renal clear cell renal cell carcinoma probably arising from mesodermal embryonic remnants. Pathology international. 2012;62(4):291-3.
10
11. Terada T. Extra-renal clear cell renal cell carcinoma probably arising from mesodermal embryonic remnants. Pathol Int. 2012;62(4):291-3.
11
12. Nunes G, Pinto-Marques P, Sequeira P, Mendonça E. Primary Extrarenal Renal Cell Carcinoma: A Unique Diagnosis Performed through Endoscopic Ultrasound. GE Port J Gastroenterol. 2019;26(5):378-80.
12
13. Chawla A, Rao M, Ithawala M, Philipraj J, Sasidharan K. Synchronous renal cell carcinoma in supernumerary and ipsilateral kidneys. Bju International. 2002;90:e11-e.
13
14. Nunes G, Pinto-Marques P, Sequeira P, Mendonça E. Primary Extrarenal Renal Cell Carcinoma: A Unique Diagnosis Performed through Endoscopic Ultrasound. GE-Portuguese Journal of Gastroenterology. 2019;26(5):378-80.
14
ORIGINAL_ARTICLE
Comparison on Diagnostic Accuracy of Prostate Cancer Detection Tools: A Systematic Review and Meta-Analysis
IntroductionSome tests and markers have proved to improve the diagnosis of prostate cancer (PCa). This meta-analysis aimed to review the diagnostic accuracy of three commercial tests, prostate health index (PHI), prostate cancer antigen 3 (PCA3), and prostate imaging reporting & data system V2 (PI-RADS) for detecting of PCa. MethodsWe did a comprehensive literature search of international databases, including Scopus, Web of Science, and PubMed, from January 2000 to Feb 2018. We included three groups of diagnostic accuracy studies that used PCA3, PHI, and PI-RADS to assess PCa. The l quality of the study was measured by the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) criteria. ResultsTwenty-six studies on PHI, 24 articles on PI-RADS, and 26 papers on PCA3 were included in the meta-analysis. For the diagnosis of PCa, the sensitivity and specificity were 0.76 and 0.84 for PI-RADS, 0.48 and 0.85 for PHI, and 0.49 and 0.79 for PCA3. Also, the derived area under curves (AUC) from the hierarchic summary ROCs (HSROCs) were 0.86 (95% CI, 0.83-0.89) for PI-RADS, 0.72 (0.68-0.76) for PCA3, and 0.70 (0.66-0.74) for PHI. Fagan’s nomograms showed that the post-test probability of cancer subjects with a positive test was 53%, 63%, and 45% for PHI, PI-RADS, and PCA3, respectively.ConclusionsAvailable evidence suggests that the PI-RADS is superior in diagnosing PCa with high sensitivity, specificity, and AUC compared to PHI and PCA3.
http://www.transresurology.com/article_106625_6d74a75457f71f3c6a972bb0cbec3259.pdf
2019-08-25
27
39
10.22034/au.2020.226654.1012
Prostate Cancer
Prostate Imaging Reporting & Data System
Prostate Health Index
Prostate Cancer Antigen 3
Diagnosis
Seyed Mohammad Kazem
Aghamir
mkaghamir@tums.ac.ir
1
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Gita
Shafiee
urc@tums.ac.ir
2
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
Mehdi
Ebrahimi
m_ebrahimi49@yahoo.com
3
Department of Internal Medicine, Faculty of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran Iran
AUTHOR
Hossein
Yarmohammadi
hosseinyarmohammadi98@gmail.com
4
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Rezvan
Razmande
r.razmandeh1388@gmail.com
5
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Hassan
Ahmadi
ahmadihasan701@gmail.com
6
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Leila
Zareian Baghdadabad
l-zareian@farabi.tums.ac.ir
7
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Ramin
Heshmat
rheshmat@tums.ac.ir
8
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
1. Teoh JY, Hirai HW, Ho JM, Chan FC, Tsoi KK, Ng CF. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One. 2019;14(10):e0221775.
1
2. Fowler JE, Jr., Bigler SA, Lynch C, Wilson SS, Farabaugh PB. Prospective study of correlations between biopsy-detected high grade prostatic intraepithelial neoplasia, serum prostate specific antigen concentration, and race. Cancer. 2001;91(7):1291-6.
2
3. Gittelman MC, Hertzman B, Bailen J, Williams T, Koziol I, Henderson RJ, et al. PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. The Journal of urology. 2013;190(1):64-9.
3
4. Loeb S, Catalona WJ. The Prostate Health Index: a new test for the detection of prostate cancer. Therapeutic advances in urology. 2014;6(2):74-7.
4
5. Porpiglia F, Russo F, Manfredi M, Mele F, Fiori C, Bollito E, et al. The roles of multiparametric magnetic resonance imaging, PCA3 and prostate health index-which is the best predictor of prostate cancer after a negative biopsy? The Journal of urology. 2014;192(1):60-6.
5
6. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. European urology. 2008;54(5):1081-8.
6
7. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. The Journal of urology. 2011;185(5):1650-5.
7
8. de la Calle C, Patil D, Wei JT, Scherr DS, Sokoll L, Chan DW, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men. The Journal of urology. 2015;194(1):65-72.
8
9. Zhang L, Tang M, Chen S, Lei X, Zhang X, Huan Y. A meta-analysis of use of Prostate Imaging Reporting and Data System Version 2 (PI-RADS V2) with multiparametric MR imaging for the detection of prostate cancer. European radiology. 2017;27(12):5204-14.
9
10. Salagierski M, Sosnowski M, Schalken JA. How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. Central European journal of urology. 2012;65(3):110-2.
10
11. Bosco C, Cozzi G, Kinsella J, Bianchi R, Acher P, Challacombe B, et al. Confirmatory biopsy for the assessment of prostate cancer in men considering active surveillance: reference centre experience. Ecancermedicalscience. 2016;10:633.
11
12. Garcia-Reyes K, Nguyen HG, Zagoria RJ, Shinohara K, Carroll PR, Behr SC, et al. Impact of Lesion Visibility on Transrectal Ultrasound on the Prediction of Clinically Significant Prostate Cancer (Gleason Score 3+4 or Greater) with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Biopsy. J Urol. 2018;199(3):699-705.
12
13. Lazzeri M, Lughezzani G, Haese A, McNicholas T, de la Taille A, Buffi NM, et al. Clinical performance of prostate health index in men with tPSA>10 ng/ml: Results from a multicentric European study. Urologic Oncology: Seminars and Original Investigations. 2016;34(9):415.e13-.e19.
13
14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
14
15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine. 2011;155(8):529-36.
15
16. Cancer incidence for common cancers / Cancer Research UK. https://wwwcancerresearchukorg/health-professional/cancer-statistics/incidence/common-cancers-compared. 2017.
16
17. Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, et al. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml? Journal of cancer research and clinical oncology. 2018.
17
18. Borkowetz A, Hadaschik B, Platzek I, Toma M, Torsev G, Renner T, et al. Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients. BJU Int. 2018;121(1):53-60.
18
19. Rosenkrantz AB, Begovic J, Pires A, Won E, Taneja SS, Babb JS. Online Interactive Case-Based Instruction in Prostate Magnetic Resonance Imaging Interpretation Using Prostate Imaging and Reporting Data System Version 2: Effect for Novice Readers. Current problems in diagnostic radiology. 2018.
19
20. Kuhl CK, Bruhn R, Kramer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated Biparametric Prostate MR Imaging in Men with Elevated Prostate-specific Antigen. Radiology. 2017;285(2):493-505.
20
21. Kim SH, Choi MS, Kim MJ, Kim YH, Cho SH. Validation of Prostate Imaging Reporting and Data System Version 2 Using an MRI-Ultrasound Fusion Biopsy in Prostate Cancer Diagnosis. Am J Roentgenol. 2017;209(4):800-5.
21
22. Gao G, Wang CY, Zhang XD, Hu J, Yang XD, Wang H, et al. Quantitative analysis of diffusion-weighted magnetic resonance images: differentiation between prostate cancer and normal tissue based on a computer-aided diagnosis system. Sci China-Life Sci. 2017;60(1):37-43.
22
23. Nougaret S, Robertson N, Golia Pernicka J, Molinari N, Hotker AM, Ehdaie B, et al. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer. Abdom Radiol (NY). 2017;42(7):1968-74.
23
24. Wang R, Wang J, Gao G, Hu J, Jiang YY, Zhao ZL, et al. Prebiopsy mp-MRI Can Help to Improve the Predictive Performance in Prostate Cancer: A Prospective Study in 1,478 Consecutive Patients. Clin Cancer Res. 2017;23(14):3692-9.
24
25. Furuya K, Kawahara T, Narahara M, Tokita T, Fukui S, Imano M, et al. Measurement of serum isoform -2 proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10ng/ml. Scand J Urol. 2017;51(4):251-7.
25
26. Kasel-Seibert M, Lehmann T, Aschenbach R, Guettler FV, Abubrig M, Grimm MO, et al. Assessment of PI-RADS v2 for the Detection of Prostate Cancer. Eur J Radiol. 2016;85(4):726-31.
26
27. El-Samei H, Amin MF, Hassan EE. Assessment of the accuracy of multi-parametric MRI with PI-RADS 2.0 scoring system in the discrimination of suspicious prostatic focal lesions. Egypt J Radiol Nucl Med. 2016;47(3):1075-82.
27
28. Feng ZY, Wang L, Min XD, Wang SG, Wang GP, Cai J. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2. Chin Med J. 2016;129(20):2451-9.
28
29. Wang X, Wang JY, Li CM, Zhang YQ, Wang JL, Wan B, et al. Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen < 20 ng/ml. Chin Med J. 2016;129(12):1432-8.
29
30. Polanec S, Helbich TH, Bickel H, Pinker-Domenig K, Georg D, Shariat SF, et al. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. Eur J Radiol. 2016;85(6):1125-31.
30
31. Sahibzada I, Batura D, Hellawell G. Validating multiparametric MRI for diagnosis and monitoring of prostate cancer in patients for active surveillance. Int Urol Nephrol. 2016;48(4):529-33.
31
32. Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, et al. Comparative Analysis of Transperineal Template Saturation Prostate Biopsy Versus Magnetic Resonance Imaging Targeted Biopsy with Magnetic Resonance Imaging-Ultrasound Fusion Guidance. J Urol. 2015;193(1):87-94.
32
33. Rastinehad AR, Waingankar N, Turkbey B, Yaskiv O, Sonstegard AM, Fakhoury M, et al. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies. PLoS One. 2015;10(11).
33
34. Wang R, Wang H, Zhao CL, Hu J, Jiang YY, Tong YJ, et al. Evaluation of Multiparametric Magnetic Resonance Imaging in Detection and Prediction of Prostate Cancer. PLoS One. 2015;10(6).
34
35. Grey ADR, Chana MS, Popert R, Wolfe K, Liyanage SH, Acher PL. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting. BJU Int. 2015;115(5):728-35.
35
36. Baur ADJ, Maxeiner A, Franiel T, Kilic E, Huppertz A, Schwenke C, et al. Evaluation of the Prostate Imaging Reporting and Data System for the Detection of Prostate Cancer by the Results of Targeted Biopsy of the Prostate. Invest Radiol. 2014;49(6):411-20.
36
37. Roethke MC, Kuru TH, Schultze S, Tichy D, Kopp-Schneider A, Fenchel M, et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. European radiology. 2014;24(2):344-52.
37
38. Junker D, Schäfer G, Edlinger M, Kremser C, Bektic J, Horninger W, et al. Evaluation of the PI-RADS scoring system for classifying mpMRI findings in men with suspicion of prostate cancer. BioMed Research International. 2013;2013.
38
39. Schimmoller L, Quentin M, Arsov C, Lanzman RS, Hiester A, Rabenalt R, et al. Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. European radiology. 2013;23(11):3185-90.
39
40. Catalona WJ, Partin AW, Sanda MG, Wei JT, Klee GG, Bangma CH, et al. A Multicenter Study of -2 Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. J Urol. 2011;185(5):1650-5.
40
41. Seisen T, Rouprêt M, Brault D, Léon P, Cancel-Tassin G, Compérat E, et al. Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate. 2015;75(1):103-11.
41
42. Filella X, Foj L, Auge JM, Molina R, Alcover J. Clinical utility of %p2PSA and prostate health index in the detection of prostate cancer. Clin Chem Lab Med. 2014;52(9):1347-55.
42
43. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu XH, et al. Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum -2 Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer. Clin Chem. 2013;59(1):280-8.
43
44. Al Saidi SS, Al Riyami NB, Al Marhoon MS, Al Saraf MS, Al Busaidi SS, Bayoumi R, et al. Validity of prostate health index and percentage of [-2] pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: Omani tertiary hospitals experience. Oman Medical Journal. 2017;32(4):275-83.
44
45. Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, et al. The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. J Urol. 2015;193(4):1163-9.
45
46. Ng CF, Chiu PKF, Lam NY, Lam HC, Lee KWM, Hou SSM. The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng/mL. Int Urol Nephrol. 2014;46(4):711-7.
46
47. Osredkar J, Kumer K, Fabjan T, Hlebic G, Podnar B, Lenart G, et al. The performance of -2 proPSA and prostate health index tumor markers in prostate cancer diagnosis. LaboratoriumsMedizin. 2016;40(6):419-24.
47
48. Lazzeri M, Haese A, De La Taille A, Palou Redorta J, McNicholas T, Lughezzani G, et al. Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng/ml: A multicentric european study. European urology. 2013;63(6):986-94.
48
49. Friedl A, Stangl K, Bauer W, Kivaranovic D, Schneeweiss J, Susani M, et al. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy. Urology. 2017;110:148-53.
49
50. Na R, Ye DW, Qi J, Liu F, Helfand BT, Brendler CB, et al. Prostate health index significantly reduced unnecessary prostate biopsies in patients with PSA 2-10 ng/mL and PSA > 10 ng/mL: Results from a Multicenter Study in China. Prostate. 2017;77(11):1221-9.
50
51. Ferro M, Bruzzese D, Perdona S, Marino A, Mazzarella C, Perruolo G, et al. Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2-10 ng/ml. PLoS One. 2013;8(7).
51
52. Tan LGL, Tan YK, Tai BC, Tan KML, Gauhar V, Tiong HY, et al. Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml(-1). Asian J Androl. 2017;19(3):286-90.
52
53. Vukovic I, Djordjevic D, Bojanic N, Babic U, Soldatovic I. Predictive value of -2 propsa ( p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range. Int Braz J Urol. 2017;43(1):48-56.
53
54. Ferro M, Bruzzese D, Perdona S, Mazzarella C, Marino A, Sorrentino A, et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta. 2012;413(15-16):1274-8.
54
55. Fuchsova R, Topolcan O, Windrichova J, Hora M, Dolejsova O, Pecen L, et al. PHI in the Early Detection of Prostate Cancer. Anticancer Res. 2015;35(9):4855-7.
55
56. Yu GP, Na R, Ye DW, Qi J, Liu F, Chen HT, et al. Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. Asian J Androl. 2016;18(4):633-8.
56
57. Lughezzani G, Lazzeri M, Haese A, McNicholas T, de la Taille A, Buffi NM, et al. Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. European urology. 2014;66(5):906-12.
57
58. Scattoni V, Lazzeri M, Lughezzani G, De Luca S, Passera R, Bollito E, et al. Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. The Journal of urology. 2013;190(2):496-501.
58
59. Mearini L, Ferri C, Lazzeri M, Bini V, Nunzi E, Fiorini D, et al. Evaluation of Prostate-Specific Antigen Isoform p2PSA and Its Derivates, %p2PSA, Prostate Health Index and Prostate Dimension-Adjusted Related Index in the Detection of Prostate Cancer at First Biopsy: An Exploratory, Prospective Study. UrolInt. 2014;93(2):135-45.
59
60. Park H, Lee SW, Song G, Kang TW, Jung JH, Chung HC, et al. Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. Journal of Korean medical science. 2018;33(11):e94.
60
61. Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, et al. Serum Index Test % -2 proPSA and Prostate Health Index are More Accurate than Prostate Specific Antigen and %fPSA in Predicting a Positive Repeat Prostate Biopsy. J Urol. 2012;188(4):1137-43.
61
62. Lughezzani G, Lazzeri M, Larcher A, Lista G, Scattoni V, Cestari A, et al. Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. The Journal of urology. 2012;188(4):1144-50.
62
63. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PFA, et al. Clinical Utility of the PCA3 Urine Assay in European Men Scheduled for Repeat Biopsy. European urology. 2008;54(5):1081-8.
63
64. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol-Semin Orig Investig. 2013;31(5):566-71.
64
65. Marks LS, Fradet Y, Lim Deras I, Blase A, Mathis J, Aubin SMJ, et al. PCA3 Molecular Urine Assay for Prostate Cancer in Men Undergoing Repeat Biopsy. Urology. 2007;69(3):532-5.
65
66. Van Gils MPMQ, Hessels D, Van Hooij O, Jannink SA, Peelen WP, Hanssen SLJ, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13(3):939-43.
66
67. Panebianco V, Sciarra A, De Berardinis E, Busetto GM, Lisi D, Buonocore V, et al. PCA3 urinary test versus 1H-MRSI and DCEMR in the detection of prostate cancer foci in patients with biochemical alterations. Anticancer Res. 2011;31(4):1399-405.
67
68. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a polish cohort. Anticancer Res. 2013;33(2):553-8.
68
69. Adam A, Engelbrecht MJ, Bornman MS, Manda SO, Moshokoa E, Feilat RA. The role of the PCA3 assay in predicting prostate biopsy outcome in a South African setting. BJU Int. 2011;108(11):1728-33.
69
70. Deras IL, Aubin SMJ, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. J Urol. 2008;179(4):1587-92.
70
71. Aubin SMJ, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184(5):1947-52.
71
72. Goode RR, Marshall SJ, Duff M, Chevli E, Chevli KK. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2013;73(1):48-53.
72
73. Hessels D, van Gils M, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive Value of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer. Prostate. 2010;70(1):10-6.
73
74. De Luca S, Passera R, Milillo A, Coda R, Randone DF. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score. BJU Int. 2012;110(11 B):E778-E82.
74
75. Nyberg M, Ulmert D, Lindgren A, Lindström U, Abrahamsson PA, Bjartell A. PCA3 as a diagnostic marker for prostate cancer: A validation study on a Swedish patient population. Scandinavian Journal of Urology and Nephrology. 2010;44(6):378-83.
75
76. Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama SI, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013;111(6):928-33.
76
77. Ramos CG, Valdevenito R, Vergara I, Anabalon P, Sanchez C, Fulla J. PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience. Urol Oncol-Semin Orig Investig. 2013;31(8):1522-6.
77
78. Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona G. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? Int Braz J Urol. 2012;38(4):489-95.
78
79. Wu AK, Reese AC, Cooperberg MR, Sadetsky N, Shinohara K. Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2012;15(1):100-5.
79
80. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT. Rational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care. Cancer. 2009;115(17):3879-86.
80
81. Busetto GM, De Berardinis E, Sciarra A, Panebianco V, Giovannone R, Rosato S, et al. Prostate Cancer Gene 3 and Multiparametric Magnetic Resonance Can Reduce Unnecessary Biopsies: Decision Curve Analysis to Evaluate Predictive Models. Urology. 2013;82(6):1355-60.
81
82. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. The Journal of urology. 2011;185(6):2119-25.
82
83. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. The Journal of urology. 2009;182(5):2232-41.
83
84. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Annals of internal medicine. 2012;157(2):120-34.
84
85. Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. European urology. 2013;64(6):876-92.
85
86. Wagenlehner FM, van Oostrum E, Tenke P, Tandogdu Z, Cek M, Grabe M, et al. Infective complications after prostate biopsy: outcome of the Global Prevalence Study of Infections in Urology (GPIU) 2010 and 2011, a prospective multinational multicentre prostate biopsy study. European urology. 2013;63(3):521-7.
86
87. Hoeks CM, Barentsz JO, Hambrock T, Yakar D, Somford DM, Heijmink SW, et al. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology. 2011;261(1):46-66.
87
88. Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. European radiology. 2012;22(4):746-57.
88
89. Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. European urology. 2016;69(1):16-40.
89
90. Cantiello F, Russo GI, Ferro M, Cicione A, Cimino S, Favilla V, et al. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. Urologic oncology. 2015;33(4):163 e15-23.
90
91. Rhodes T, Jacobson DJ, McGree ME, St Sauver JL, Sarma AV, Girman CJ, et al. Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men. The Journal of urology. 2012;187(1):92-6.
91
92. Lazzeri M, Briganti A, Scattoni V, Lughezzani G, Larcher A, Gadda GM, et al. Serum index test %[-2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. The Journal of urology. 2012;188(4):1137-43.
92
93. Salagierski M, Verhaegh GW, Jannink SA, Smit FP, Hessels D, Schalken JA. Differential expression of PCA3 and its overlapping PRUNE2 transcript in prostate cancer. Prostate. 2010;70(1):70-8.
93
94. Clarke RA, Zhao Z, Guo AY, Roper K, Teng L, Fang ZM, et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One. 2009;4(3):e4995.
94
95. Pepe P, Fraggetta F, Galia A, Skonieczny G, Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cut-off: 20 or 35? International braz j urol : official journal of the Brazilian Society of Urology. 2012;38(4):489-95.
95
96. Filella X, Gimenez N. Evaluation of [-2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2013;51(4):729-39.
96
97. Xue WJ, Ying XL, Jiang JH, Xu YH. Prostate cancer antigen 3 as a biomarker in the urine for prostate cancer diagnosis: a meta-analysis. Journal of cancer research and therapeutics. 2014;10 Suppl:C218-21.
97
98. Porpiglia F, Cantiello F, De Luca S, Manfredi M, Veltri A, Russo F, et al. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance. BJU Int. 2016;118(4):527-34.
98
99. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. Journal of clinical epidemiology. 2003;56(11):1129-35.
99
ORIGINAL_ARTICLE
Efficacy of Additional Solifenacin Succinate Therapy in Females with Urinary Tract Infection
Urinary tract infection (UTI) is a collective word for diseases involving any portion of the urinary tract and it’s the most common infection in local primary care that has suffered from it by up to 60 percent of females and has at least one symptomatic UTI in a lifetime. UTI can have consequences like kidney infection, infections of the urinary tract, and, eventually, toxic septicemia. UTI is often confused with wide-spectrum antibiotics, so it is imperative to characterize resistance patterns to enhance in-vitro antibiotic strategies. According to previous studies, the use of anticholinergics to relieve UTI symptoms has never been investigated. This research is the first randomized trial of anticholinergic-like solifenacin succinate (with a strong affinity for smooth muscle receptors M3) to treat and improve UTI.
http://www.transresurology.com/article_106626_a9102cb7d823aef97a751c5ee0a74214.pdf
2019-08-27
40
42
10.22034/au.2020.227867.1017
Solifenacin Succinate
female
Urinary tract infection
Behzad
Narouie
b_narouie@yahoo.com
1
Department of Urology, Zahedan University of Medical Sciences, Zahedan, Iran
AUTHOR
Akram
Mirzaei
mirzaee.scholar@gmail.com
2
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Guglietta A. Recurrent urinary tract infections in women: risk factors, etiology, pathogenesis and prophylaxis. Future Microbiology. 2017;12(3):239-46.
1
2. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Annals of internal medicine. 2001;135(1):41-50.
2
3. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Annals of clinical microbiology and antimicrobials. 2007;6(1):4.
3
4. Roberts KB. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128(3):595-610.
4
5. Geerlings SE. Clinical presentations and epidemiology of urinary tract infections. Urinary Tract Infections: Molecular Pathogenesis and Clinical Management. 2017:27-40.
5
6. Chapple C, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. European urology. 2005;48(3):464-70.
6
7. Maniscalco M, Singh-Franco D, Wolowich WR, Torres-Colón R. Solifenacin succinate for the treatment of symptoms of overactive bladder. Clinical therapeutics. 2006;28(9):1247-72.
7
8. Ohtake A, Saitoh C, Yuyama H, Ukai M, Okutsu H, Noguchi Y, et al. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biological and Pharmaceutical Bulletin. 2007;30(1):54-8.
8
9. Rahardjo HE, Syahputra FA, Islianti PI, Matondang FA. Efficacy of Additional Solifenacin Succinate Therapy for Storage Symptoms in Females with Uncomplicated Lower Urinary Tract Infection: The SOLUTION Randomized Controlled Trial. Acta Medica Indonesiana. 2018;50(3):200-7.
9
10. Maman K, Aballea S, Nazir J, Desroziers K, Neine M-E, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. European urology. 2014;65(4):755-65.
10
11. Basra R, Kelleher C. A review of solifenacin in the treatment of urinary incontinence. Therapeutics and clinical risk management. 2008;4(1):117.
11
12. Kosilov KV, Loparev SA, Ivanovskaya MA, Kosilova LV. The efficacy of different doses of solifenacin in elderly patients after treating a urinary tract infection. Arab journal of urology. 2015;13(3):203-8.
12
ORIGINAL_ARTICLE
Ultrasound-Guided Paravertebral Block compare to the Intravenous Tramadol for Pain Control in Percutaneous Nephrolithotomy
< p>Percutaneous nephrolithotomy (PCNL) is a standard treatment method for large choroidal stones with a shorter hospital stay than surgical procedures. After PCNL, a nephrostomy tube is placed for better discharge of urine, to prevent bleeding, and allow for further possible operations, which is can be the major cause of pain and discomfort for the patient. Paravertebral block (PVB) is a successful, non-complicating local anesthetic used in many surgical procedures to manage pain. It is suggested that using PVB to reduce pain after PCNL has had good results. In the previous study, the important problem of post-PCNL pain reduction has been properly managed by the PVB method, and its high efficacy, contrary to tramadol, has been demonstrated. Evaluation of the PVB method is a good choice in this regard, but the question arises as to why Tramadol is selected as a method compared to PVB.
http://www.transresurology.com/article_106627_f4ecb24c502c9f5c8dbf5dbbb4957c09.pdf
2019-08-17
43
45
10.22034/au.2020.228227.1016
pain control
Percutaneous nephrolithotomy
nephrolithotomy
Vahid
shokohideh
va.shokohideh@gmail.com
1
Department of Medicine, Jiroft University of Medical Sciences, Tehran, Iran
AUTHOR
Rahil
Mashhadi
rh_mashhadi@yahoo.com
2
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
LEAD_AUTHOR
1. Akbay EK, Koç G, Filiz ND, Ün S, Akdeniz F, Yilmaz Y. Does a prilocaine 2% injection into the nephrostomy tract have a role in acute pain management after a lower caliceal puncture during a percutaneous nephrolithotomy? A prospective randomized study with 100 patients/PNL operasyonu alt kaliks girisi sonrasi trakta% 2 prilokain enjeksiyonunun akut agri kontrolündeki etkinligi; 100 hastalik prospektif randomize calisma. Turkish Journal of Urology. 2012;38(2):69.
1
2. Zanetti SP, Boeri L, Catellani M, Gallioli A, Trinchieri A, Sarica K, et al. Retrograde intrarenal surgery (RIRS), regular and small sized percutaneous nephrolithotomy (PCNL) in daily practice: European Association of Urology Section of Urolithiasis (EULIS) Survey. Archivio Italiano di Urologia e Andrologia. 2016;88(3):212-6.
2
3. Gokten OE, Kilicarslan H, Dogan HS, Turker G, Kordan Y. Efficacy of levobupivacaine infiltration to nephrosthomy tract in combination with intravenous paracetamol on postoperative analgesia in percutaneous nephrolithotomy patients. Journal of endourology. 2011;25(1):35-9.
3
4. Yuan H, Zheng S, Liu L, Han P, Wang J, Wei Q. The efficacy and safety of tubeless percutaneous nephrolithotomy: a systematic review and meta-analysis. Urological research. 2011;39(5):401-10.
4
5. Ak K, Gursoy S, Duger C, Isbir A, Kaygusuz K, Kol IO, et al. Thoracic paravertebral block for postoperative pain management in percutaneous nephrolithotomy patients: a randomized controlled clinical trial. Medical Principles and Practice. 2013;22(3):229-33.
5
6. Dundar G, Gokcen K, Gokce G, Gultekin EY. The Effect of Local Anesthetic Agent Infiltration Around Nephrostomy Tract On Postoperative Pain Control After Percutaneous Nephrolithotomy: A single-centre, randomised, double-blind, placebocontrolled clinical trial. Urology journal. 2018;15(6):306-12.
6
7. Tüzel E, Kızıltepe G, Akdoğan B. The effect of local anesthetic infiltration around nephrostomy tract on postoperative pain control after percutaneous nephrolithotomy. Urolithiasis. 2014;42(4):353-8.
7
8. Greengrass R, Buckenmaier III CC. Paravertebral anaesthesia/analgesia for ambulatory surgery. Best Practice & Research Clinical Anaesthesiology. 2002;16(2):271-83.
8
9. Jamieson BD, Mariano ER. Thoracic and lumbar paravertebral blocks for outpatient lithotripsy. Journal of clinical anesthesia. 2007;19(2):149-51.
9
10. Klein SM, Bergh A, Steele SM, Georgiade GS, Greengrass RA. Thoracic paravertebral block for breast surgery. Anesthesia & Analgesia. 2000;90(6):1402-5.
10
11. Hatipoglu Z, Gulec E, Turktan M, Izol V, Arıdogan A, Gunes Y, et al. Comparative study of ultrasound-guided paravertebral block versus intravenous tramadol for postoperative pain control in percutaneous nephrolithotomy. BMC anesthesiology. 2018;18(1):24.
11
12. Yalcin I, Aksu F, Bodard S, Chalon S, Belzung C. Antidepressant-like effect of tramadol in the unpredictable chronic mild stress procedure: possible involvement of the noradrenergic system. Behavioural pharmacology. 2007;18(7):623-31.
12
13. Hassamal S, Miotto K, Dale W, Danovitch I. Tramadol: understanding the risk of serotonin syndrome and seizures. The American journal of medicine. 2018;131(11):1382.
13
ORIGINAL_ARTICLE
Novel Surgical Strategy for Treatment of Abnormal Cavernous (Balloon-Like Penile) Resulting in Sex Disability
IntroductionCavernous malformations can result in erectile dysfunction and sex disability. Several treatment strategies are available, and we introduce a novel surgery method with vascular mesh.Case presentationA 23-years old man had a normal erection, but he could not perform coitus, and his penis bent. He was operated on for ventral chordee with a misdiagnosis of chordee and then treated with an injection of papaverine because of the misdiagnosis of erectile dysfunction (ED), but the problem remained unsolved. We decide to have a novel surgery method using vascular mesh. Our surgery was completely successful, and our new method of surgery can take the place of penile implants for such cases.ConclusionsOur technique with vascular mesh can be considered the most efficient method to make the cavernous retain its normal function.
http://www.transresurology.com/article_106628_fa5dc61654040e34ed1385a4558ca861.pdf
2019-08-21
46
50
10.22034/au.2020.228327.1018
vascular mesh
erecrtile dysfunction
Surgery
Seyed Amin
Mirsadeghi
dr.mirsadeghi@gmail.com
1
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Mohammad
Aslzare
mohamamadasle@gmail.com
2
Department of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
LEAD_AUTHOR
1. Weiss HD. The physiology of human penile erection. Annals of internal Medicine. 1972;76(5):793-9.
1
2. Avery LL, Scheinfeld MH. Imaging of penile and scrotal emergencies. Radiographics. 2013;33(3):721-40.
2
3. Bhatt S, Kocakoc E, Rubens DJ, Seftel AD, Dogra VS. Sonographic evaluation of penile trauma. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 2005;24(7):993-1000; quiz 1.
3
4. Hatzimouratidis K, Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, et al. Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015). The journal of sexual medicine. 2016;13(4):465-88.
4
5. Ayta I, McKinlay J, Krane R. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU international. 1999;84(1):50-6.
5
6. Hatzimouratidis K, Eardley I, Giuliano F, Hatzichristou D, Moncada I, Salonia A, et al. EAU guidelines on penile curvature. European urology. 2012;62(3):543-52.
6
7. Mobley EM, Fuchs ME, Myers JB, Brant WO. Update on plication procedures for Peyronie’s disease and other penile deformities. Therapeutic advances in urology. 2012;4(6):335-46.
7
8. Leonardo C, De Nunzio C, Michetti P, Tartaglia N, Tubaro A, De Dominicis C, et al. Plication corporoplasty versus Nesbit operation for the correction of congenital penile curvature. A long-term follow-up. International urology and nephrology. 2012;44(1):55-60.
8
9. Nesbit RM. Operation for correction of distal penile ventral curvature with or without hypospadias. The Journal of urology. 1967;97(4):720-2.
9
10. Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis: new implant for management of impotence. Urology. 1975;5(4):479-86.
10
11. Minervini A, Ralph DJ, Pryor JP. Outcome of penile prosthesis implantation for treating erectile dysfunction: experience with 504 procedures. BJU international. 2006;97(1):129-33.
11
12. Bennett N, Henry G, Karpman E, Brant W, Jones L, Khera M, et al. Inflatable penile prosthesis implant length with baseline characteristic correlations: preliminary analysis of the PROPPER study. Translational andrology and urology. 2017;6(6):1167.
12
13. Thomalla JV, Thompson ST, Rowland RG, Mulcahy JJ. Infectious complications of penile prosthetic implants. The Journal of urology. 1987;138(1):65-7.
13
14. Wilson SK, Delk JR. Inflatable penile implant infection: predisposing factors and treatment suggestions. The Journal of urology. 1995;153(3):659-61.
14